FDA grants second approval for Retevmo

Shares of US pharma major Eli Lilly (NYSE: LLY) edged up 1.4% to $300.68 pre-market today, on the news that its RET kinase inhibitor Retevmo (selpercatinib) had received a second approval in the USA.

The Food and Drug Administration granted accelerated approval to Retevmo (selpercatinib) for adults with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

In May 2020, the FDA approved Retevmo to treat non-small cell lung cancer (NSCLC), medullary thyroid cancer, and other types of thyroid cancers in patients whose tumors have an alteration in a specific gene.